Abstract
Although levodopa remains the most efficacious symptomatic therapy for Parkinson disease (PD), management of levodopa treatment during the advanced stages of the disease is extremely challenging. This difficulty is a result of levodopa’s short half-life, a progressive narrowing of the therapeutic window, and major inter-patient and intra-patient variations in the dose–response relationship. Therefore, a suitable alternative to repeated oral administration of levodopa is being sought. Recent research efforts have focused on the development of novel levodopa delivery strategies and wearable physical sensors that track symptoms and disease progression. However, the need for methods to monitor the levels of levodopa present in the body in real time has been overlooked. Advances in chemical sensor technology mean that the development of wearable and mobile biosensors for continuous or frequent levodopa measurements is now possible. Such levodopa monitoring could help to deliver personalized and timely medication dosing to alleviate treatment-related fluctuations in the symptoms of PD. Therefore, with the aim of optimizing therapeutic management of PD and improving the quality of life of patients, we share our vision of a future closed-loop autonomous wearable ‘sense-and-act’ system. This system consists of a network of physical and chemical sensors coupled with a levodopa delivery device and is guided by effective big data fusion algorithms and machine learning methods.
Similar content being viewed by others
References
Parkinson, J. An essay on the shaking palsy. J. Neuropsychiatry Clin. Neurosci. 14, 223–236 (2002).
de Lau, L. M. L. & Breteler, M. M. B. Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525–535 (2006).
Connolly, B. S. & Lang, A. E. Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670–1683 (2014).
Nord, M. Levodopa pharmacokinetics — from stomach to brain — a study on patients with Parkinson’s disease. Thesis (Linköping University, 2017).
Monje, M. H. G., Foffani, G., Obeso, J. & Sánchez-Ferro, Á. New sensor and wearable technologies to aid in the diagnosis and treatment monitoring of Parkinson’s disease. Annu. Rev. Biomed. Eng. 21, 111–143 (2019).
Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).
Yang, W. et al. Current and projected future economic burden of Parkinson’s disease in the US. NPJ Park. Dis. 6, 15 (2020).
Charvin, D., Medori, R., Hauser, R. A. & Rascol, O. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat. Rev. Drug Discov. 17, 804–822 (2018).
Birkmayer, W. & Hornykiewicz, O. Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-syndrom des menschen: zur pathogenese und behandlung der Parkinson-Akinese. Arch. Psychiatr. Nervenkr. 203, 560–574 (1962).
Nutt, J. G. & Holford, N. H. G. The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann. Neurol. 39, 561–573 (1996).
Hornykiewicz, O. A brief history of levodopa. J. Neurol. 257, 249–252 (2010).
Abbott, A. Levodopa: the story so far. Nature 466, S6–S7 (2010).
Obeso, J. A., Olanow, C. W. & Nutt, J. G. Levodopa motor complications in Parkinson’s disease. Trends Neurosci. 23, S2–S7 (2000).
Urso, D., Chaudhuri, K. R., Qamar, M. A. & Jenner, P. Improving the delivery of levodopa in Parkinson’s disease: a review of approved and emerging therapies. CNS Drugs 34, 1149–1163 (2020).
Rovini, E., Maremmani, C. & Cavallo, F. How wearable sensors can support Parkinson’s disease diagnosis and treatment: a systematic review. Front. Neurosci. 11, 555 (2017).
Barbosa, W., Zhou, K., Waddell, E., Myers, T. & Dorsey, E. R. Improving access to care: telemedicine across medical domains. Annu. Rev. Public Health 42, 463–481 (2021).
van den Bergh, R., Bloem, B. R., Meinders, M. J. & Evers, L. J. W. The state of telemedicine for persons with Parkinson’s disease. Curr. Opin. Neurol. 34, 589–597 (2021).
Delrobaei, M. et al. Towards remote monitoring of Parkinson’s disease tremor using wearable motion capture systems. J. Neurol. Sci. 384, 38–45 (2018).
Evers, L. J. W., Krijthe, J. H., Meinders, M. J., Bloem, B. R. & Heskes, T. M. Measuring Parkinson’s disease over time: the real-world within-subject reliability of the MDS-UPDRS. Mov. Disord. 34, 1480–1487 (2019).
AlMahadin, G. et al. Parkinson’s disease: current assessment methods and wearable devices for evaluation of movement disorder motor symptoms — a patient and healthcare professional perspective. BMC Neurol. 20, 419 (2020).
Teymourian, H. et al. Wearable electrochemical sensors for the monitoring and screening of drugs. ACS Sens. 5, 2679–2700 (2020).
Kim, J., Campbell, A. S., de Ávila, B. E. F. & Wang, J. Wearable biosensors for healthcare monitoring. Nat. Biotechnol. 37, 389–406 (2019).
Choi, J. et al. Bio-integrated wearable systems: a comprehensive review. Chem. Rev. 119, 5461–5533 (2019).
Teymourian, H., Barfidokht, A. & Wang, J. Electrochemical glucose sensors in diabetes management: an updated review (2010–2020). Chem. Soc. Rev. 49, 7671–7709 (2020).
Gao, W. et al. Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis. Nature 529, 509–514 (2016).
Goetz, C. G., Stebbins, G. T., Blasucci, L. M. & Grobman, M. S. Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson’s disease. Mov. Disord. 12, 1039–1041 (1997).
Espay, A. J. et al. Technology in Parkinson’s disease: challenges and opportunities. Mov. Disord. 31, 1272–1282 (2016).
Rovini, E., Maremmani, C. & Cavallo, F. Automated systems based on wearable sensors for the management of Parkinson’s disease at home: a systematic review. Telemed. J. E. Health 25, 167–183 (2018).
Sundgren, M., Andréasson, M., Svenningsson, P., Noori, R.-M. & Johansson, A. Does information from the Parkinson KinetiGraphTM (PKG) influence the neurologist’s treatment decisions? — An observational study in routine clinical care of people with Parkinson’s disease. J. Pers. Med. 11, 519 (2021).
Rob, P. et al. Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson’s disease. Sci. Transl. Med. 13, eabd7865 (2021).
Heldman, D. A. et al. App-based bradykinesia tasks for clinic and home assessment in Parkinson’s disease: reliability and responsiveness. J. Parkinsons Dis. 7, 741–747 (2017).
Pulliam, C. L. et al. Continuous assessment of levodopa response in Parkinson’s disease using wearable motion sensors. IEEE Trans. Biomed. Eng. 65, 159–164 (2018).
Vittal, P. et al. Does added objective tremor monitoring improve clinical outcomes in essential tremor treatment? Mov. Disord. Clin. Pract. 5, 96–98 (2018).
Nahab, F. B., Abu-Hussain, H. & Moreno, L. Evaluation of clinical utility of the personal KinetiGraph® in the management of Parkinson disease. Adv. Park. Dis. 8, 42–61 (2019).
Pahwa, R. et al. Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel. Expert Rev. Neurother. 18, 669–680 (2018).
Fokkenrood, H. J. P. et al. Physical activity monitoring in patients with peripheral arterial disease: validation of an activity monitor. Eur. J. Vasc. Endovasc. Surg. 48, 194–200 (2014).
Taylor, L. M. et al. Validation of a body-worn accelerometer to measure activity patterns in octogenarians. Arch. Phys. Med. Rehabil. 95, 930–934 (2014).
Yeung, J. et al. Evaluating the sensoria smart socks gait monitoring system for rehabilitation outcomes. PMR 11, 512–521 (2019).
Universitat Politècnica De Catalunya BarcelonaTech. STAT-ON, a new device that helps monitor the symptoms of patients with Parkinson’s. Universitat Politècnica De Catalunya BarcelonaTech https://www.upc.edu/en/press-room/news/stat-on-a-new-device-that-helps-monitor-the-symptoms-of-patients-with-parkinson2019s (2019).
Pérez-López, C. et al. Assessing motor fluctuations in Parkinson’s disease patients based on a single inertial sensor. Sensors 16, 2132 (2016).
Samà, A. et al. Estimating bradykinesia severity in Parkinson’s disease by analysing gait through a waist-worn sensor. Comput. Biol. Med. 84, 114–123 (2017).
Piromalis, D. D. et al. Commercially available sensor-based monitoring and support systems in Parkinson’s disease: an overview. 2021 8th International Conference on Computing for Sustainable Global Development (INDIACom) 430–438 (IEEE, 2021).
Washabaugh, E. P., Kalyanaraman, T., Adamczyk, P. G., Claflin, E. S. & Krishnan, C. Validity and repeatability of inertial measurement units for measuring gait parameters. Gait Posture 55, 87–93 (2017).
Morris, R. et al. Validity of mobility Lab (version 2) for gait assessment in young adults, older adults and Parkinson’s disease. Physiol. Meas. 40, 95003 (2019).
Zampieri, C. et al. The instrumented timed up and go test: Potential outcome measure for disease modifying therapies in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 81, 171–176 (2010).
Mancini, M. & Horak, F. B. Potential of APDM mobility lab for the monitoring of the progression of Parkinson’s disease. Expert Rev. Med. Devices 13, 455–462 (2016).
Weiss, D. et al. Long-term outcome of deep brain stimulation in fragile X-associated tremor/ataxia syndrome. Park. Relat. Disord. 21, 310–313 (2015).
Lyons, K. E. & Pahwa, R. The impact and management of nonmotor symptoms of Parkinson’s disease. Am. J. Manag. Care 17, S308–S314 (2011).
Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of parkinson disease: a review. JAMA 323, 548–560 (2020).
Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 435–450 (2017).
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
Velseboer, D. C., de Haan, R. J., Wieling, W., Goldstein, D. S. & de Bie, R. M. A. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Park. Relat. Disord. 17, 724–729 (2011).
Shahdost-Fard, F., Bigdeli, A. & Hormozi-Nezhad, M. R. A smartphone-based fluorescent electronic tongue for tracing dopaminergic agents in human urine. ACS Chem. Neurosci. 12, 3157–3166 (2021).
Chen, C. et al. Blue and green emission-transformed fluorescent copolymer: specific detection of levodopa of anti-Parkinson drug in human serum. Talanta 214, 120817 (2020).
Wang, L., Su, D., Berry, S. N., Lee, J. & Chang, Y.-T. A new approach for turn-on fluorescence sensing of l-DOPA. Chem. Commun. 53, 12465–12468 (2017).
Park, S. W., Kim, T. E. & Jung, Y. K. Glutathione-decorated fluorescent carbon quantum dots for sensitive and selective detection of levodopa. Anal. Chim. Acta 1165, 338513 (2021).
Brunetti, B., Valdés-Ramírez, G., Litvan, I. & Wang, J. A disposable electrochemical biosensor for l-DOPA determination in undiluted human serum. Electrochem. Commun. 48, 28–31 (2014).
Goud, K. Y. et al. Wearable electrochemical microneedle sensor for continuous monitoring of levodopa: toward Parkinson management. ACS Sens. 4, 2196–2204 (2019).
Tai, L.-C. et al. Wearable sweat band for noninvasive levodopa monitoring. Nano Lett. 19, 6346–6351 (2019).
Moon, J.-M. et al. Non-invasive sweat-based tracking of L-dopa pharmacokinetic profiles following an oral tablet administration. Angew. Chem. Int. Ed. 60, 19074–19078 (2021).
Yang, Y. & Gao, W. Wearable and flexible electronics for continuous molecular monitoring. Chem. Soc. Rev. 18, 1465–1491 (2019).
Bandodkar, A. J. & Wang, J. Non-invasive wearable electrochemical sensors: a review. Trends Biotechnol. 32, 363–371 (2014).
Tang, W. et al. Touch-based stressless cortisol sensing. Adv. Mater. 33, 2008465 (2021).
Lin, S. et al. Natural perspiration sampling and in situ electrochemical analysis with hydrogel micropatches for user-identifiable and wireless chemo/biosensing. ACS Sens. 5, 93–102 (2020).
Teymourian, H., Tehrani, F., Mahato, K. & Wang, J. Lab under the skin: microneedle based wearable devices. Adv. Healthc. Mater. 10, 2002255 (2021).
Samant, P. P. et al. Sampling interstitial fluid from human skin using a microneedle patch. Sci. Transl. Med. 12, eaaw0285 (2020).
Tran, B. Q. et al. Proteomic characterization of dermal interstitial fluid extracted using a novel microneedle-assisted technique. J. Proteome Res. 17, 479–485 (2018).
Nilsson, A. K., Sjöbom, U., Christenson, K. & Hellström, A. Lipid profiling of suction blister fluid: comparison of lipids in interstitial fluid and plasma. Lipids Health Dis. 18, 164 (2019).
Niedzwiecki, M. M. et al. Human suction blister fluid composition determined using high-resolution metabolomics. Anal. Chem. 90, 3786–3792 (2018).
Kolluru, C., Williams, M., Chae, J. & Prausnitz, M. R. Recruitment and collection of dermal interstitial fluid using a microneedle patch. Adv. Healthc. Mater. 8, 1801262 (2019).
Rawson, T. M. et al. Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. Lancet Digit. Health 1, e335–e343 (2019).
Tehrani, F. et al. An integrated wearable microneedle array for the continuous monitoring of multiple biomarkers in interstitial fluid. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-022-00887-1 (2022).
Senek, M. & Nyholm, D. Continuous drug delivery in Parkinson’s disease. CNS Drugs 28, 19–27 (2014).
Dhall, R. & Kreitzman, D. L. Advances in levodopa therapy for Parkinson disease. Neurology 86, S13–S24 (2016).
Tsunemi, T. et al. Intrajejunal Infusion of levodopa/carbidopa for advanced Parkinson’s disease: a systematic review. Mov. Disord. 36, 1759–1771 (2021).
Olanow, C. W. et al. Continuous subcutaneous levodopa delivery for Parkinson’s disease: a randomized study. J. Park. Dis. 11, 177–186 (2021).
Ray Chaudhuri, K. et al. Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future. NPJ Park. Dis. 2, 16023 (2016).
Bogachkov, Y. Y. JUBIwatch device targets medication adherence. Parkinson’s News Today https://parkinsonsnewstoday.com/2021/11/02/jubiwatch-medication-management-device-parkinsons-disease/ (2021).
Frankel, J. P., Lees, A. J., Kempster, P. A. & Stern, G. M. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 53, 96–101 (1990).
Trenkwalder, C. et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease–clinical practice recommendations. Park. Relat. Disord. 21, 1023–1030 (2015).
LeWitt, P. A. Subcutaneously administered apomorphine. Neurology 62, S8–S11 (2004).
Pahwa, R. et al. Early morning akinesia in Parkinson’s disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. Neurology 46, 1059–1062 (1996).
Kempster, P. A. et al. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 52, 718–723 (1989).
Antonini, A. & Tolosa, E. Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev. Neurother. 9, 859–867 (2009).
Olanow, C. W., Poewe, W., Rascol, O. & Stocchi, F. On-demand therapy for OFF episodes in Parkinson’s disease. Mov. Disord. 36, 2244–2253 (2021).
Hauser, R. A., LeWitt, P. A. & Comella, C. L. On demand therapy for Parkinson’s disease patients: opportunities and choices. Postgrad. Med. 133, 721–727 (2021).
Amjad, F. et al. Current practices for outpatient initiation of levodopa-carbidopa intestinal gel for management of advanced Parkinson’s disease in the United States. Adv. Ther. 36, 2233–2246 (2019).
Müller, T. An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease. Expert Opin. Pharmacother. 21, 1659–1665 (2020).
Nutt, J. G. & Woodward, W. R. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36, 739 (1986).
Nutt, J. G., Carter, J. H., Lea, E. S. & Woodward, W. R. Motor fluctuations during continuous levodopa infusions in patients with Parkinson’s disease. Mov. Disord. 12, 285–292 (1997).
Gancher, S. T., Nutt, J. G. & Woodward, W. R. Time course of tolerance to apomorphine in parkinsonism. Clin. Pharmacol. Ther. 52, 504–510 (1992).
Nutt, J. G. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 23, S580–S584 (2008).
Scholten, K. & Meng, E. A review of implantable biosensors for closed-loop glucose control and other drug delivery applications. Int. J. Pharm. 544, 319–334 (2018).
Khodaei, M. J., Candelino, N., Mehrvarz, A. & Jalili, N. Physiological closed-loop control (PCLC) systems: review of a modern frontier in automation. IEEE Access. 8, 23965–24005 (2020).
Schmitzer, J., Strobel, C., Blechschmidt, R., Tappe, A. & Peuscher, H. Efficient closed loop simulation of do-it-yourself artificial pancreas systems. J. Diabetes Sci. Technol. 16, 61–69 (2021).
Wolkowicz, K. L. et al. A review of biomarkers in the context of type 1 diabetes: biological sensing for enhanced glucose control. Bioeng. Transl. Med. 6, e10201 (2021).
Espay, A. J., Brundin, P. & Lang, A. E. Precision medicine for disease modification in Parkinson disease. Nat. Rev. Neurol. 13, 119–126 (2017).
Lang, A. E. & Espay, A. J. Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov. Disord. 33, 660–677 (2018).
Luis-Martínez, R., Monje, M. H. G., Antonini, A., Sánchez-Ferro, Á. & Mestre, T. A. Technology-enabled care: integrating multidisciplinary care in Parkinson’s disease through digital technology. Front. Neurol. 11, 575975 (2020).
Wang, C. et al. Monitoring of the central blood pressure waveform via a conformal ultrasonic device. Nat. Biomed. Eng. 2, 687–695 (2018).
Goud, K. Y. et al. Wearable electrochemical microneedle sensing platform for real-time continuous interstitial fluid monitoring of apomorphine: toward Parkinson management. Sens. Actuators B Chem. 354, 131234 (2022).
Ji, D. et al. Smartphone-based square wave voltammetry system with screen-printed graphene electrodes for norepinephrine detection. Smart Mater. Med. 1, 1–9 (2020).
Imani, S. et al. A wearable chemical–electrophysiological hybrid biosensing system for real-time health and fitness monitoring. Nat. Commun. 7, 11650 (2016).
Sempionatto, J. R. et al. An epidermal patch for the simultaneous monitoring of haemodynamic and metabolic biomarkers. Nat. Biomed. Eng. 5, 737–748 (2021).
Belić, M. et al. Artificial intelligence for assisting diagnostics and assessment of Parkinson’s disease — a review. Clin. Neurol. Neurosurg. 184, 105442 (2019).
Patel, S. et al. Monitoring motor fluctuations in patients with Parkinson’s disease using wearable sensors. IEEE Trans. Inf. Technol. Biomed. 13, 864–873 (2009).
Nancy Jane, Y., Khanna Nehemiah, H. & Arputharaj, K. A Q-backpropagated time delay neural network for diagnosing severity of gait disturbances in Parkinson’s disease. J. Biomed. Inform. 60, 169–176 (2016).
Lawton, M. et al. Parkinson’s disease subtypes in the Oxford Parkinson Disease Centre (OPDC) discovery cohort. J. Park. Dis. 5, 269–279 (2015).
Brichta, L., Greengard, P. & Flajolet, M. Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. Trends Neurosci. 36, 543–554 (2013).
LeWitt, P. A. Norepinephrine: the next therapeutics frontier for Parkinson’s disease. Transl. Neurodegener. 1, 4 (2012).
Devos, D., Defebvre, L. & Bordet, R. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease. Fundam. Clin. Pharmacol. 24, 407–421 (2010).
Stocchi, F. Prevention and treatment of motor fluctuations. Park. Relat. Disord. 9, 73–81 (2003).
Dijk, J. M., Espay, A. J., Katzenschlager, R. & de Bie, R. M. A. The choice between advanced therapies for Parkinson’s disease patients: why, what, and when? J. Park. Dis. 10, S65–S73 (2020).
Larson, D. & Simuni, T. New dopaminergic therapies for PD motor complications. Neuropharmacology 204, 108869 (2022).
Athauda, D. & Foltynie, T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat. Rev. Neurol. 11, 25–40 (2015).
Kim, K. S. Toward neuroprotective treatments of Parkinson’s disease. Proc. Natl Acad. Sci. USA 114, 3795–3797 (2017).
Salamon, A., Zádori, D., Szpisjak, L., Klivényi, P. & Vécsei, L. Neuroprotection in Parkinson’s disease: facts and hopes. J. Neural Transm. 127, 821–829 (2020).
Savitt, D. & Jankovic, J. Targeting α-synuclein in Parkinson’s disease: progress towards the development of disease-modifying therapeutics. Drugs 79, 797–810 (2019).
Genius, J. et al. Results from a phase 1b study of UCB0599, an orally available, brain-penetrant inhibitor of alphasynuclein (ASYN) misfolding in people living with Parkinson’s disease (PD) (2025). Neurology 96, 2025 (2021).
Sardi, S. P. & Simuni, T. New era in disease modification in Parkinson’s disease: review of genetically targeted therapeutics. Park. Relat. Disord. 59, 32–38 (2019).
Nutt, J. G. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69–73 (2003).
Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459–466 (2006).
Axelsen, T. M. & Woldbye, D. P. D. Gene therapy for Parkinson’s disease, an update. J. Parkinsons Dis. 8, 195–215 (2018).
Chen, W., Huang, Q., Ma, S. & Li, M. Progress in dopaminergic cell replacement and regenerative strategies for Parkinson’s disease. ACS Chem. Neurosci. 10, 839–851 (2019).
Kim, T. W., Koo, S. Y. & Studer, L. Pluripotent stem cell therapies for Parkinson disease: present challenges and future opportunities. Front. Cell Dev. Biol. 8, 729 (2020).
Hung, A. Y. & Schwarzschild, M. A. Approaches to disease modification for Parkinson’s disease: clinical trials and lessons learned. Neurotherapeutics 17, 1393–1405 (2020).
Kalia, L. V., Kalia, S. K. & Lang, A. E. Disease-modifying strategies for Parkinson’s disease. Mov. Disord. 30, 1442–1450 (2015).
Silva, R. C., Domingues, H. S., Salgado, A. J. & Teixeira, F. G. From regenerative strategies to pharmacological approaches: can we fine-tune treatment for Parkinson’s disease? Neural Regen. Res. 17, 933–936 (2022).
Del Din, S., Kirk, C., Yarnall, A. J., Rochester, L. & Hausdorff, J. M. Body-worn sensors for remote monitoring of Parkinson’s disease motor symptoms: vision, state of the art, and challenges ahead. J. Park. Dis. 11, S35–S47 (2021).
Dorsey, E. R., Bloem, B. R. & Okun, M. S. A new day: the role of telemedicine in reshaping care for persons with movement disorders. Mov. Disord. 35, 1897–1902 (2020).
Evans, L., Mohamed, B. & Thomas, E. C. Using telemedicine and wearable technology to establish a virtual clinic for people with Parkinson’s disease. BMJ Open Qual. 9, e001000 (2020).
Barker, R. A. et al. GDNF and Parkinson’s disease: where next? A summary from a recent workshop. J. Park. Dis. 10, 875–891 (2020).
Jankovic, J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov. Disord. 20, S11–S16 (2005).
Vijiaratnam, N. & Foltynie, T. Therapeutic strategies to treat or prevent off episodes in adults with Parkinson’s disease. Drugs 80, 775–796 (2020).
Acknowledgements
The authors’ work is supported by the NIH National Institute of Neurological Disorders and Stroke (grant number R21 NS114764-01A1).
Author information
Authors and Affiliations
Contributions
H.T., F.T. and K.L. along with J.W. and I.L. all contributed to researching data for the article, discussing the content and writing the article, as well as editing before submission. K.M. contributed to researching data for the article, discussing the content and writing the article. T.P., J.M., Y.G.K. and J.S. contributed to researching data for the article and discussing the content.
Corresponding authors
Ethics declarations
Competing interests
J.W.’s research is supported by the National Institutes of Health (NIH) grant 1R21NS114764-01A1. I.L.’s research is supported by the NIH grants 2R01AG038791-06A, U01NS100610, U01NS80818, R25NS098999, U19 AG063911-1 and 1R21NS114764-01A1, the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Abbvie, Biogen, Biohaven Pharmaceuticals, Brain Neurotherapy Bio, Centogene, EIP Pharma, Novartis, Roche, United Biopharma and UCB. She is a Scientific adviser for Amydis and The Rossy Center for Progressive Supranuclear Palsy at the University of Toronto. K.L.’s research is partially supported by NIH grant 1R21NS114764-01A1. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Neurology thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
HeartGuide: https://omronhealthcare.com/products/heartguide-wearable-blood-pressure-monitor-bp8000m/
Kinesia 360: http://glneurotech.com/kinesia/products/kinesia-360/
MoveMonitor: https://www.mcroberts.nl/products/movemonitor/
Personal Kinetigraph: https://pkgcare.com/
SleepImage: https://sleepimage.com/
Glossary
- Accelerometers
-
Electronic tools that measure linear acceleration along one or several axes.
- Amperometric transduction
-
The electrochemical recording of current signals; a constant potential is maintained between the electrodes, with the resulting current related to the concentration of a target biomarker.
- Bradykinesia
-
Slowness in the execution of movement; also implies hypokinesia (low amplitude) of the movement.
- Chemical sensors
-
Devices capable of converting a chemical quantity into a measurable signal.
- Diffusion mechanism
-
The underlying mechanism governing the diffusion of biomolecules from blood capillaries to other bodily fluids such as interstitial fluid or sweat.
- Disposable electrode strip
-
An electrode pattern, usually screen-printed on semi-rigid plastic material, for one-time measurements of a chemical quantity.
- Dyskinesias
-
Involuntary, erratic, rocking, twisting or writhing movements reflecting high levodopa levels.
- Electrochemical devices
-
Devices that quantify the concentration of target analytes (for example, drugs, biomarkers or metabolites) by converting electrode–analyte interactions into measurable electrical signals (that is, current or voltage).
- Freezing of gait
-
Brief episodes during which the patient is unable to generate active stepping movements.
- Gyroscopes
-
Devices that measure angular rotational velocity, also known as angular velocity sensors.
- Holter device
-
A monitoring device consisting of signal recording hardware and data analysis software; this technology is most commonly used for monitoring heart rhythm and rate.
- Internal consistency testing
-
Assessing the correlation between multiple items in a single test to provide a measure of the reliability of the test overall.
- Magnetometers
-
Devices that measure orientation by sensing the direction of the earth’s magnetic field; ideal for measuring falls and changes in position (seated versus standing).
- Microneedle sensor patches
-
An epidermal device with micro-dimensional needle-shaped projections that attach painlessly to the skin for minimally invasive detection of biomarkers.
- ‘Off’ states
-
When medication is no longer working well and parkinsonian symptoms re-emerge.
- ‘On’ states
-
When a patient experiences a good response to medication and parkinsonian symptoms (for example, tremor, stiffness, slowness) are well controlled.
- Test–retest reliability
-
A measure of reliability, where the given test is applied twice over a period of time to the same group of individuals.
- The Internet of things
-
A network of physical objects that can connect and exchange data over the internet through their embedded sensors, software and other technologies.
- Voltammetric
-
The electrochemical recording of current signals by varying the applied potential between the electrodes.
Rights and permissions
About this article
Cite this article
Teymourian, H., Tehrani, F., Longardner, K. et al. Closing the loop for patients with Parkinson disease: where are we?. Nat Rev Neurol 18, 497–507 (2022). https://doi.org/10.1038/s41582-022-00674-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00674-1
- Springer Nature Limited
This article is cited by
-
A decision support system based on recurrent neural networks to predict medication dosage for patients with Parkinson's disease
Scientific Reports (2024)
-
PARK7/DJ-1 in microglia: implications in Parkinson’s disease and relevance as a therapeutic target
Journal of Neuroinflammation (2023)
-
Digital health for aging populations
Nature Medicine (2023)
-
Expanding causal genes for Parkinson’s disease via multi-omics analysis
npj Parkinson's Disease (2023)